Compare Davita Inc (DVA) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs F5 Inc — how do they compare? Davita Inc trades at $178.35 (market cap $11.72B), while F5 Inc trades at $415.62 (market cap $23.22B). The key difference: F5 Inc is the larger of the two by market cap, and F5 Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | FFIV | |
|---|---|---|
Market Cap | $11.72B | $23.22B |
Sector | Health | Technology |
52-Week High | $240.96 | $431.26 |
52-Week Low | $103.87 | $223.99 |
Enterprise Value | $24.44B | $21.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
F5 (FFIV) trades at $400.23, down 3.11% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with EPS of $4.73 versus $4.00 expected, and raised its fiscal outlook, driven by 19% product revenue growth. Fundamentals show robust profitability with a net income margin of 21.95% and consistent revenue growth, though valuation ratios like a P/E of 31.89 appear elevated. Analyst sentiment is mixed with a 40% buy rating.
The outlook is cautiously optimistic given earnings momentum and raised guidance, but risks include high valuation and competitive pressures. The consensus price target of $430.43 suggests modest upside potential from current levels, contingent on sustained execution in application security and hybrid cloud demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
